{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

2nd European MS Awareness Day

source: The European MS Platform (EMSP)

2nd MS Awareness Day on Tuesday, November 21, 2006 in the European Parliament.

read more

back to top

Profile of the Month : January 2008

Meg Kingston

Country: Wales
Age: 40-something
Year of diagnosis: late 1990s
Occupation: writer and former IT consultant

English Italiano Deutsh Espanol Francais Russian

read more

back to top

Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis.

This study explores the immunological effects of interferon teatement in PPMS. PPMS patients demonstrated a different pattern of cytokine release from T cells compared to patients with RRMS.

authors: Dressel A, Kolb AK, Elitok E, Bitsch A, Bogumil T, Kitze B, Tumani H, Weber F.

source: Acta Neurol Scand. 2006 Dec;114(6):368-73

read more

IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions.

This study investigated the role of Intravenous immunoglobulin (IVIG) in reducing relapses in RRMS, using a rat model of MS. It was found that IVIG can only cross the blood brain barrier into the CSF (fluid around the brain) in areas where the barrier is damaged by inflammation.

authors: Jorgensen SH, Storm N, Jensen PE, Laursen H, Sorensen PS.

source: Exp Brain Res. 2006 Nov 8; [Epub ahead of print]

read more

Localization of grey matter atrophy in early RRMS : A longitudinal study.

This study in early RRMS investigates areas of irreversible tissue loss, or atrophy. Atrophy was not present at the start of the study but developed over the two year period, and the amount of atrophy related to the clinical status of patients.

authors: Audoin B, Davies GR, Finisku L, Chard DT, Thompson AJ, Miller DH.

source: J Neurol. 2006 Nov 8; [Epub ahead of print}

read more

Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis.

This study explores the role of polymorphisms in the ACE (Angiotensin-converting enzyme) gene in susceptibility to MS. Deletions of this gene were found to be commoner in male patients with MS than in healthy controls.

authors: Lovrecic L, Ristic S, Starcevic-Cizmarevic N, Jazbec SS, Sepcic J, Kapovic M, Peterlin B.

source: Acta Neurol Scand. 2006 Dec;114(6):374-7.

read more

Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.

This study in 16 patients with MS found an increase in certain immune cell subtypes (CD8+) in MS compared to controls in the blood, but a decrease in these cells within the brain fluid (CSF).

authors: Haegele KF, Stueckle CA, Malin JP, Sindern E.

source: J Neuroimmunol. 2006 Nov 3; [Epub ahead of print]

read more

back to top

News from New Zealand MS Society

source: New Zealand MS Society

The latest roundup of recent news from the New Zealand MS Society is now available.

read more

Sex hormone trial in women with MS launched

source: US national MS society

The first large-scale trial of a sex hormone for the treatment of MS is about to begin.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.